| Year |
Citation |
Score |
| 2023 |
Kalaitsidou M, Moon OR, Sykorova M, Bao L, Qu Y, Sukumaran S, Valentine M, Zhou X, Pandey V, Foos K, Medvedev S, Powell DJ, Udyavar A, Gschweng E, Rodriguez R, ... Dudley ME, et al. Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes. Frontiers in Immunology. 14: 1256491. PMID 38022678 DOI: 10.3389/fimmu.2023.1256491 |
0.584 |
|
| 2021 |
Schmidt E, Mardilovich K, Bath N, Betts G, Spinner W, Sun K, Donaldson I, McAlpine C, Luke R, Navenot J, Sanderson J, Bassett P, Evans C, Miller K, Lin Q, ... Dudley M, et al. 373 Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion Journal For Immunotherapy of Cancer. 9: A401-A401. DOI: 10.1136/jitc-2021-sitc2021.373 |
0.535 |
|
| 2020 |
Hong D, Clarke J, Johanns T, Kebriaei P, Heymach J, Galal A, Saibil S, Sacher A, Brophy F, Betts G, Bath N, William S, Tipping A, Tucci J, Luke R, ... ... Dudley M, et al. 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor Journal For Immunotherapy of Cancer. 8: A404-A404. DOI: 10.1136/jitc-2020-sitc2020.0379 |
0.528 |
|
| 2020 |
Mardilovich K, Wang L, Kenneil R, Betts G, Bath N, Spinner W, Mello VD, Lwin S, Sanderson J, Silk J, Tipping A, Gerry A, Bassett P, Miller K, Dudley M, et al. 95 Inhibition of AKT signaling during expansion of TCR-engineered T-cells from patient leukocyte material generates SPEAR T-cells with enhanced functional potential in vitro Journal For Immunotherapy of Cancer. 8: A106-A106. DOI: 10.1136/jitc-2020-sitc2020.0095 |
0.568 |
|
| 2017 |
Xue Q, Bettini E, Paczkowski P, Ng C, Kaiser A, McConnell T, Kodrasi O, Quigley MF, Heath J, Fan R, Mackay S, Dudley ME, Kassim SH, Zhou J. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response. Journal For Immunotherapy of Cancer. 5: 85. PMID 29157295 DOI: 10.1186/S40425-017-0293-7 |
0.769 |
|
| 2016 |
Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, et al. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27217459 DOI: 10.1200/Jco.2016.66.7220 |
0.343 |
|
| 2016 |
Wang J, Dudley M, Choquette T, Jeschke M, Rutjens E, Kassim S. An Innovative in Vitro Potency Assay Designed to Predict the Fate of Chimeric Antigen Receptors Modified T Cell Therapy Post Infusion in ALL Blood. 128: 5830-5830. DOI: 10.1182/Blood.V128.22.5830.5830 |
0.756 |
|
| 2015 |
Stevanovi? S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1543-50. PMID 25823737 DOI: 10.1200/Jco.2014.58.9093 |
0.328 |
|
| 2015 |
Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2278-88. PMID 25695689 DOI: 10.1158/1078-0432.Ccr-14-2085 |
0.641 |
|
| 2015 |
Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1019-27. PMID 25538264 DOI: 10.1158/1078-0432.Ccr-14-2708 |
0.746 |
|
| 2015 |
Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Dudley ME, Somerville R, Wunderlich JR, Sherry RM, Yang JC, Rosenberg SA, Kammula US. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 534-43. PMID 25424856 DOI: 10.1158/1078-0432.Ccr-14-2208 |
0.506 |
|
| 2015 |
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 540-9. PMID 25154820 DOI: 10.1200/Jco.2014.56.2025 |
0.762 |
|
| 2014 |
Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3401-10. PMID 24987109 DOI: 10.1158/1078-0432.CCR-14-0433 |
0.426 |
|
| 2014 |
Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (New York, N.Y.). 344: 641-5. PMID 24812403 DOI: 10.1126/science.1251102 |
0.504 |
|
| 2014 |
Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. The Journal of Clinical Investigation. 124: 2246-59. PMID 24667641 DOI: 10.1172/JCI73639 |
0.399 |
|
| 2013 |
Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, Ascierto ML, De Giorgi V, Liu Q, Delogu LG, Sommariva M, Sertoli MR, Simon R, Wang E, Rosenberg SA, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. British Journal of Cancer. 109: 2412-23. PMID 24129241 DOI: 10.1038/bjc.2013.557 |
0.334 |
|
| 2013 |
Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 122: 4129-39. PMID 24055823 DOI: 10.1182/Blood-2013-08-519413 |
0.775 |
|
| 2013 |
Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, Dudley ME, Rosenberg SA. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. Journal of Immunology (Baltimore, Md. : 1950). 191: 2217-25. PMID 23904171 DOI: 10.4049/jimmunol.1300538 |
0.569 |
|
| 2013 |
Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, Scheffold A. Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunology, Immunotherapy : Cii. 62: 1563-73. PMID 23903715 DOI: 10.1007/s00262-013-1459-x |
0.599 |
|
| 2013 |
Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. Journal of Immunology (Baltimore, Md. : 1950). 190: 6034-42. PMID 23690473 DOI: 10.4049/jimmunol.1202830 |
0.452 |
|
| 2013 |
Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2152-9. PMID 23650429 DOI: 10.1200/Jco.2012.46.6441 |
0.435 |
|
| 2013 |
Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 133-51. PMID 23377668 DOI: 10.1097/Cji.0B013E3182829903 |
0.323 |
|
| 2013 |
Kochenderfer JN, Dudley ME, Kassim SH, Carpenter RO, Yang JC, Phan GQ, Hughes MS, Sherry RM, Feldman S, Spaner D, Nathan DN, Morton KE, Toomey MA, Rosenberg SA. Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor Blood. 122: 168-168. DOI: 10.1182/Blood.V122.21.168.168 |
0.776 |
|
| 2013 |
Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford W, Hakim FT, Halverson D, Fowler DH, Hardy NM, Mato A, Hickstein DD, Gea-Banacloche J, Pavletic SZ, Sportes C, et al. Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation Blood. 122: 151-151. DOI: 10.1182/Blood.V122.21.151.151 |
0.781 |
|
| 2012 |
Somerville RP, Dudley ME. Bioreactors get personal. Oncoimmunology. 1: 1435-1437. PMID 23243620 DOI: 10.4161/onci.21206 |
0.341 |
|
| 2012 |
Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Science Translational Medicine. 4: 149ra120. PMID 22932225 DOI: 10.1126/Scitranslmed.3004306 |
0.514 |
|
| 2012 |
Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5212-23. PMID 22837179 DOI: 10.1158/1078-0432.CCR-12-1108 |
0.474 |
|
| 2012 |
Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, Li YF, Robbins PF, Besser MJ, ... ... Dudley ME, et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology. 1: 409-418. PMID 22754759 DOI: 10.4161/Onci.18851 |
0.594 |
|
| 2012 |
Alvarez-Downing MM, Inchauste SM, Dudley ME, White DE, Wunderlich JR, Rosenberg SA, Kammula US. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. World Journal of Surgical Oncology. 10: 113. PMID 22726267 DOI: 10.1186/1477-7819-10-113 |
0.347 |
|
| 2012 |
Seaman BJ, Guardiani EA, Brewer CC, Zalewski CK, King KA, Rudy S, Van Waes C, Morgan RA, Dudley ME, Yang JC, Rosenberg SA, Kim HJ. Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 147: 744-9. PMID 22597578 DOI: 10.1177/0194599812448356 |
0.337 |
|
| 2012 |
Zhang L, Feldman SA, Zheng Z, Chinnasamy N, Xu H, Nahvi AV, Dudley ME, Rosenberg SA, Morgan RA. Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 430-9. PMID 22576348 DOI: 10.1097/CJI.0b013e31825898e8 |
0.32 |
|
| 2012 |
Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 400-8. PMID 22576345 DOI: 10.1097/CJI.0b013e31825898c5 |
0.439 |
|
| 2012 |
Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 119: 5688-96. PMID 22555974 DOI: 10.1182/blood-2011-10-386482 |
0.519 |
|
| 2012 |
Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews. Immunology. 12: 269-81. PMID 22437939 DOI: 10.1038/Nri3191 |
0.516 |
|
| 2012 |
Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ, Rao M, Restifo NP, et al. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. Journal of Translational Medicine. 10: 48. PMID 22420641 DOI: 10.1186/1479-5876-10-48 |
0.495 |
|
| 2012 |
Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 246-9. PMID 22297819 DOI: 10.1038/Mt.2011.288 |
0.496 |
|
| 2012 |
Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119: 2709-20. PMID 22160384 DOI: 10.1182/blood-2011-10-384388 |
0.64 |
|
| 2012 |
Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, Van Rooij N, Linnemann C, Van Buuren MM, Urbanus JHM, Beltman JB, Straten P, Li YF, Robbins PF, Besser MJ, ... ... Dudley ME, et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients Oncoimmunology. 1: 409-418. DOI: 10.4161/onci.18851 |
0.557 |
|
| 2012 |
Turcotte S, Gros A, Wunderlich JR, Hogan K, Wang QJ, Fetsch P, Dudley ME, Rosenberg SA. Study of tumor-infiltrating T-cell reactivity to metastatic gastrointestinal cancers. Journal of Clinical Oncology. 30: e14179-e14179. DOI: 10.1200/jco.2012.30.15_suppl.e14179 |
0.485 |
|
| 2011 |
Friedman KM, Devillier LE, Feldman SA, Rosenberg SA, Dudley ME. Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 651-61. PMID 21989413 DOI: 10.1097/CJI.0b013e31823284c3 |
0.546 |
|
| 2011 |
Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6287-97. PMID 21844012 DOI: 10.1158/1078-0432.CCR-11-1347 |
0.455 |
|
| 2011 |
Dudley ME. Adoptive cell therapy for patients with melanoma. Journal of Cancer. 2: 360-2. PMID 21716716 DOI: 10.7150/jca.2.360 |
0.475 |
|
| 2011 |
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4550-7. PMID 21498393 DOI: 10.1158/1078-0432.Ccr-11-0116 |
0.451 |
|
| 2011 |
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 917-24. PMID 21282551 DOI: 10.1200/Jco.2010.32.2537 |
0.547 |
|
| 2011 |
Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 620-6. PMID 21157437 DOI: 10.1038/Mt.2010.272 |
0.49 |
|
| 2011 |
Kochenderfer JN, Dudley ME, Feldman S, Wilson WH, Spaner D, Devillier L, Carpenter R, Nathan DN, Maric I, Morgan RA, Rosenberg SA. B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor Blood. 118: 167-167. DOI: 10.1182/Blood.V118.21.167.167 |
0.677 |
|
| 2011 |
Kochenderfer J, Dudley M, Maric I, Feldman S, Salit R, Hardy N, Layton P, Blacklock-Schuver B, Wilder J, Devillier L, Gress R, Morgan R, Rosenberg S, Bishop M. Dramatic Regression of Chronic Lymphocytic Leukemia in the First Patient Treated With Donor-Derived Genetically-Engineered Anti-CD19-Chimeric-Antigen-Receptor-Expressing T Cells After Allogeneic Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 17: S158. DOI: 10.1016/J.BBMT.2010.12.025 |
0.552 |
|
| 2010 |
Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer Journal (Sudbury, Mass.). 16: 336-41. PMID 20693844 DOI: 10.1097/PPO.0b013e3181eb3879 |
0.576 |
|
| 2010 |
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 116: 4099-102. PMID 20668228 DOI: 10.1182/blood-2010-04-281931 |
0.666 |
|
| 2010 |
Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6122-31. PMID 20668005 DOI: 10.1158/1078-0432.Ccr-10-1297 |
0.396 |
|
| 2010 |
Yang S, Dudley ME, Rosenberg SA, Morgan RA. A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 648-58. PMID 20551831 DOI: 10.1097/CJI.0b013e3181e311cb |
0.595 |
|
| 2010 |
Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 547-56. PMID 20463593 DOI: 10.1097/CJI.0b013e3181d367bd |
0.438 |
|
| 2010 |
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 843-51. PMID 20179677 DOI: 10.1038/mt.2010.24 |
0.525 |
|
| 2010 |
Casati A, Schmitz J, Abken H, Chmielewski M, Nahvi A, Dudley M, Assenmacher M, Scheffold A. Clinical Scale Central Memory T Cell Enrichment for Adoptive T Cell Therapy Blood. 116: 5180-5180. DOI: 10.1182/BLOOD.V116.21.5180.5180 |
0.608 |
|
| 2010 |
Kochenderfer JN, Dudley ME, Stetler-Stevenson M, Wilson WH, Janik JE, Nathan DN, Maric I, Raffeld M, Feldman SA, Morgan RA, Rosenberg SA. A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells Blood. 116: 2865-2865. DOI: 10.1182/BLOOD.V116.21.2865.2865 |
0.676 |
|
| 2009 |
Smith FO, Klapper JA, Wunderlich JR, Rosenberg SA, Dudley ME. Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 870-4. PMID 19752747 DOI: 10.1097/CJI.0b013e3181b36b69 |
0.422 |
|
| 2009 |
Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 114: 535-46. PMID 19451549 DOI: 10.1182/Blood-2009-03-211714 |
0.495 |
|
| 2009 |
Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 114: 1537-44. PMID 19423728 DOI: 10.1182/blood-2008-12-195792 |
0.399 |
|
| 2009 |
Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 116: 981-989.e1. PMID 19410956 DOI: 10.1016/J.Ophtha.2008.12.004 |
0.308 |
|
| 2009 |
Klapper JA, Thomasian AA, Smith DM, Gorgas GC, Wunderlich JR, Smith FO, Hampson BS, Rosenberg SA, Dudley ME. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. Journal of Immunological Methods. 345: 90-9. PMID 19389403 DOI: 10.1016/j.jim.2009.04.009 |
0.52 |
|
| 2009 |
Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Current Opinion in Immunology. 21: 233-40. PMID 19304471 DOI: 10.1016/j.coi.2009.03.002 |
0.55 |
|
| 2008 |
Theoret MR, Cohen CJ, Dudley ME, Morgan RA, Rosenberg SA. In vitro and in vivo studies of human lymphocytes genetically engineered to express T cell receptors that recognize a p53 antigenic epitope. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3032. PMID 27947569 DOI: 10.1200/jco.2008.26.15_suppl.3032 |
0.548 |
|
| 2008 |
Theoret MR, Cohen CJ, Nahvi AV, Ngo LT, Suri KB, Powell DJ, Dudley ME, Morgan RA, Rosenberg SA. Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Human Gene Therapy. 19: 1219-32. PMID 19848582 DOI: 10.1089/HUM.2008.083 |
0.439 |
|
| 2008 |
Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5233-9. PMID 18809613 DOI: 10.1200/Jco.2008.16.5449 |
0.351 |
|
| 2008 |
Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 742-51. PMID 18779745 DOI: 10.1097/CJI.0b013e31818403d5 |
0.396 |
|
| 2008 |
Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, Zheng Z, Shelton TE, Matsuda K, Robbins PF, Morgan RA, Rosenberg SA. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Human Gene Therapy. 19: 496-510. PMID 18444786 DOI: 10.1089/hum.2007.0171 |
0.323 |
|
| 2008 |
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Reviews. Cancer. 8: 299-308. PMID 18354418 DOI: 10.1038/Nrc2355 |
0.35 |
|
| 2008 |
Kochenderfer J, Feldman S, Zhao Y, Xu H, Black M, Morgan R, Dudley M, Wilson W, Rosenberg S. Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor Blood. 112: 4623-4623. DOI: 10.1182/BLOOD.V112.11.4623.4623 |
0.634 |
|
| 2007 |
Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Seminars in Oncology. 34: 524-31. PMID 18083376 DOI: 10.1053/j.seminoncol.2007.09.002 |
0.439 |
|
| 2007 |
Santomasso BD, Roberts WK, Thomas A, Williams T, Blachère NE, Dudley ME, Houghton AN, Posner JB, Darnell RB. A T-cell receptor associated with naturally occurring human tumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 104: 19073-8. PMID 18045792 DOI: 10.1073/Pnas.0704336104 |
0.513 |
|
| 2006 |
Johnson LA, Heemskerk B, Powell DJ, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 177: 6548-59. PMID 17056587 DOI: 10.4049/Jimmunol.177.9.6548 |
0.479 |
|
| 2006 |
Powell DJ, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. Journal of Immunology (Baltimore, Md. : 1950). 177: 6527-39. PMID 17056585 DOI: 10.4049/Jimmunol.177.9.6527 |
0.45 |
|
| 2006 |
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (New York, N.Y.). 314: 126-9. PMID 16946036 DOI: 10.1126/Science.1129003 |
0.531 |
|
| 2005 |
Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, Li Y, Wunderlich J, Hawley RG, Moayeri M, Rosenberg SA, Morgan RA. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Human Gene Therapy. 16: 457-72. PMID 15871677 DOI: 10.1089/hum.2005.16.457 |
0.59 |
|
| 2005 |
Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 258-67. PMID 15838383 DOI: 10.1097/01.Cji.0000158855.92792.7A |
0.552 |
|
| 2005 |
Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2346-57. PMID 15800326 DOI: 10.1200/Jco.2005.00.240 |
0.37 |
|
| 2005 |
Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 53-62. PMID 15614045 DOI: 10.1097/00002371-200501000-00007 |
0.523 |
|
| 2005 |
Powell DJ, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 105: 241-50. PMID 15345595 DOI: 10.1182/blood-2004-06-2482 |
0.604 |
|
| 2004 |
Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. Journal of Immunology (Baltimore, Md. : 1950). 173: 7622-9. PMID 15585890 DOI: 10.4049/Jimmunol.173.12.7622 |
0.508 |
|
| 2004 |
Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ, Rosenberg SA. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. Journal of Immunology (Baltimore, Md. : 1950). 173: 7125-30. PMID 15585832 DOI: 10.4049/Jimmunol.173.12.7125 |
0.521 |
|
| 2004 |
Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 101: 14639-45. PMID 15381769 DOI: 10.1073/pnas.0405730101 |
0.45 |
|
| 2004 |
Nagorsen D, Servis C, Lévy N, Provenzano M, Dudley ME, Marincola FM, Lévy F. Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M. Cancer Immunology, Immunotherapy : Cii. 53: 817-24. PMID 15133631 DOI: 10.1007/s00262-004-0532-x |
0.301 |
|
| 2004 |
Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. Journal of Immunology (Baltimore, Md. : 1950). 172: 6057-64. PMID 15128789 DOI: 10.4049/Jimmunol.172.10.6057 |
0.445 |
|
| 2003 |
Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 385-93. PMID 12973027 DOI: 10.1097/00002371-200309000-00001 |
0.417 |
|
| 2003 |
Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. Journal of Immunology (Baltimore, Md. : 1950). 171: 3287-95. PMID 12960359 DOI: 10.4049/Jimmunol.171.6.3287 |
0.42 |
|
| 2003 |
Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nature Reviews. Cancer. 3: 666-75. PMID 12951585 DOI: 10.1038/nrc1167 |
0.425 |
|
| 2003 |
Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 332-42. PMID 12843795 DOI: 10.1097/00002371-200307000-00005 |
0.327 |
|
| 2003 |
Dudley ME. To bead or not to bead. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 187-9. PMID 12806272 DOI: 10.1097/00002371-200305000-00002 |
0.562 |
|
| 2002 |
Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. Journal of Immunology (Baltimore, Md. : 1950). 169: 6036-47. PMID 12421991 DOI: 10.4049/jimmunol.169.10.6036 |
0.499 |
|
| 2002 |
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York, N.Y.). 298: 850-4. PMID 12242449 DOI: 10.1126/Science.1076514 |
0.471 |
|
| 2002 |
Monsurrò V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM. Functional heterogeneity of vaccine-induced CD8(+) T cells. Journal of Immunology (Baltimore, Md. : 1950). 168: 5933-42. PMID 12023400 DOI: 10.4049/jimmunol.168.11.5933 |
0.527 |
|
| 2002 |
Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 25: 243-51. PMID 12000866 DOI: 10.1097/00002371-200205000-00007 |
0.366 |
|
| 2001 |
Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 363-73. PMID 11565838 DOI: 10.1097/00002371-200107000-00012 |
0.511 |
|
| 2001 |
Monsurrò V, Nielsen MB, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, Marincola FM. Kinetics of TCR use in response to repeated epitope-specific immunization. Journal of Immunology (Baltimore, Md. : 1950). 166: 5817-25. PMID 11313426 DOI: 10.4049/jimmunol.166.9.5817 |
0.408 |
|
| 2001 |
Karas M, Zaks TZ, Yakar S, Dudley ME, LeRoith D. TCR stimulation protects CD8+ T cells from CD95 mediated apoptosis. Human Immunology. 62: 32-8. PMID 11165713 DOI: 10.1016/S0198-8859(00)00223-8 |
0.531 |
|
| 2000 |
Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. Journal of Immunology (Baltimore, Md. : 1950). 164: 562-5. PMID 10623795 DOI: 10.4049/Jimmunol.164.2.562 |
0.571 |
|
| 1996 |
Dudley ME, Roopenian DC. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. The Journal of Experimental Medicine. 184: 441-7. PMID 8760797 DOI: 10.1084/Jem.184.2.441 |
0.37 |
|
| 1994 |
Zuberi AR, Dudley ME, Christianson GJ, Roopenian DC. Gene Mapping in a Murine Cell Line by Immunoselection with Cytotoxic T Lymphocytes Genomics. 19: 273-279. PMID 7514566 DOI: 10.1006/Geno.1994.1058 |
0.322 |
|
| 1989 |
Dudley ME, Long SR. A non-nodulating alfalfa mutant displays neither root hair curling nor early cell division in response to Rhizobium meliloti The Plant Cell. 1: 65-72. PMID 2535468 DOI: 10.1105/Tpc.1.1.65 |
0.497 |
|
| 1987 |
Dudley ME, Jacobs TW, Long SR. Microscopic studies of cell divisions induced in alfalfa roots by Rhizobium meliloti Planta. 171: 289-301. DOI: 10.1007/Bf00398674 |
0.444 |
|
| Show low-probability matches. |